La catena delle opzioni mostra i dati chiave delle opzioni azionarie di AIM ImmunoTech a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per AIM ImmunoTech..

AIM ImmunoTech (AMEX:AIM) Azioni, Catena delle Opzioni

AIM ImmunoTech

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

News

General

AIM ImmunoTech Receives NYSE Notification Regarding Noncompliance With Minimum Stockholders' Equity Requirements

Biotech

AIM ImmunoTech Announces It Has Resumed Trading On NYSE

Reported Friday, AIM ImmunoTech Receives NYSE American Delisting Notice Due To Low Stock Price, Plans To Appeal

WIIM

AIM ImmunoTech shares are trading lower after the company announced it entered into a $3 million equity distribution agreement with Maxim Group for an at-the-market offering

Offerings

AIM ImmunoTech Enters $3M Equity Distribution Agreement With Maxim Group For "At the Market" Offering

U.S. stocks traded lower this morning, with the Dow Jones index dipping more than 1,100 points on Friday. China unveiled a retaliatory 34% tariff on U.S. goods—mirroring the rate announced by President Donald Trump on Wednesday—deepening fears of a full-blown trade war.
The Dow traded down 2.82% to 39,401.43 while the NASDAQ fell 3.59% to 15,955.66. The S&amp;P 500 also fell, dropping, 3.20% to 5,223.96.
Check This Out: <a href="https://www.benzinga.com/25/04/44644881/top-3-financial-stocks-that-may-fall-off-a-cliff-in-april">Top 3 Financial Stocks That May Fall Off A Cliff In April</a>
Leading and Lagging Sectors Consumer staples shares fell by just 0.5% on Friday.
In trading on Friday, energy shares tumbled by 5.2%.
Top Headline
In March, nonfarm payrolls surged by 228,000, the Bureau of Labor Statistics reported Friday. The outcome is well above the three-month average of 195,000 and topped economists&#8217; forecasts of 135,000. February's employment growth was downwardly revised to 117,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) shares shot up 84% to $0.8522.</li>
<li>Shares of iCoreConnect Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCT#NASDAQ">ICCT</a>)got a boost, surging 79% to $7.59.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) shares were also up, gaining 51% to $9.77.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares dropped 44% to $0.4781 lower following its $8 million stock offering.</li>
<li>Shares of Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) were down 28% to $0.3027.</li>
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) was down, falling 39% to $0.0723.</li>
</ul>
Commodities In commodity news, oil traded down 7.8% to $61.72 while gold traded down 1% at $3,090.30.
Silver traded down 4.1% to $30.665 on Friday, while copper fell 6.9% to $4.4950.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 4.2%, Germany's DAX 40 dipped 4.2% and France's CAC 40 fell 3.8%. Spain's IBEX 35 Index fell 5.1%, while London's FTSE 100 dipped 3.8%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 dipping 2.75% and India's BSE Sensex falling 1.22%.
Economics
<ul>
<li>In March, nonfarm payrolls surged by 228,000, the Bureau of Labor Statistics reported Friday. The outcome is well above the three-month average of 195,000 and topped economists&#8217; forecasts of 135,000. February's employment growth was downwardly revised to 117,000.</li>
<li>The unemployment rate unexpectedly inched higher from 4.1% to 4.2%, defying expectations for no change.</li>
<li>Average hourly earnings increased 0.3% from February&#8217;s pace, as predicted, and rose 3.8% year-over-year, marginally lower than the 3.9% predicted.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44645517/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ICCT

NMTC

PTIX

USAR

Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March

Shares of Xos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) rose sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/XOS">reported 2024 results</a>.
The company reported its 2024 revenue surged to $56 million, compared to $44.5 million in 2023. The company delivered 297 units in 2024, up from 283 units in the previous year. Its GAAP gross margins improved from a negative 2.9% in 2023 to a positive 7.1% in 2024.
Xos shares jumped 9% to $3.75 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) gained 75.3% to $0.1402 in pre-market trading after falling over 22% on Friday.</li>
<li>Citius Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) rose 50.4% to $1.00 in pre-market trading.</li>
<li>Color Star Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) rose 50% to $1.20 in pre-market trading after falling around 5% on Friday.</li>
<li>iCoreConnect Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCT#NASDAQ">ICCT</a>) gained 37.2% to $0.3910 in pre-market trading after dipping more than 17% on Friday.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) gained 30.1% to $4.45 in pre-market trading after gaining around 12% on Friday. QuantaSing Group, last week, expanded into pop toys market with strategic acquisition of Letsvan.</li>
<li>Know Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNW#NYSE">KNW</a>) rose 19.2% to $0.8701 in pre-market trading after declining 5% on Friday.</li>
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) surged 15.5% to $0.1397 in pre-market trading. AIM ImmunoTech, last week, posted upbeat FY 2024 results.</li>
<li>China Yuchai International Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYD#NYSE">CYD</a>) gained 7.7% to $17.96 in pre-market after declining 8% on Friday.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) gained 6.3% to $20.99 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares fell 48.3% to $0.0176 in pre-market trading after dipping 23% on Friday.</li>
<li>Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) fell 37.7% to $7.00 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) fell 19.9% to $9.21 in pre-market trading. The company, last week, reported fourth-quarter financial results and beat its EPS and revenue estimates.</li>
<li>Hillman Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) declined 19.5% to $7.00 in pre-market trading.</li>
<li>Enzo Biochem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) fell 18.7% to $0.35 in pre-market trading. Enzo Biochem announced plans to voluntarily delist its common stock from the new York Stock Exchange.</li>
<li>Arhaus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) dipped 18.3% to $7.00 in pre-market trading after tumbling over 8% on Friday.</li>
<li>NeOnc Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares dipped 17.7% to $14.00 in pre-market trading.</li>
<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) shares tumbled 15.3% to $0.0288 in pre-market trading after falling over 20% on Friday.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) fell 14.3% to $15.40 in today's pre-market trading.</li>
<li>Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) shares fell 8.1% to $14.40 in pre-market trading after gaining 7% on Friday.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/03/44534977/jim-cramer-healthpeak-properties-is-a-reasonable-reit-recommends-buying-this-health-care-stock">Jim Cramer: Healthpeak Properties Is A &#8216;Reasonable&#8217; REIT, Recommends Buying This Health Care Stock</a></li>
</ul>

ARHS

BASE

CAPR

CDNA

CTOR

DGLY

HLMN

NTHI

TILE

Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

<h3>Companies Reporting Before The Bell</h3>
• Super League Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) is projected to report quarterly loss at $0.31 per share on revenue of $5.50 million. 
• Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) is expected to report earnings for its fourth quarter. 
• AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $130.50 million. 
• SBC Medical Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBC#NASDAQ">SBC</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $56.85 million. 
• Katapult Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>) is likely to report quarterly loss at $1.09 per share on revenue of $62.35 million. 
• LiqTech Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $3.80 million. 
• Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is expected to report earnings for its fourth quarter. 
• China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) is projected to report earnings for its fourth quarter. 
• So-Young Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SY#NASDAQ">SY</a>) is expected to report earnings for its fourth quarter. 
• ZSPACE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSPC#NASDAQ">ZSPC</a>) is likely to report quarterly loss at $0.09 per share on revenue of $9.61 million. 
• ImmunoPrecise Antibodies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) is likely to report quarterly loss at $0.06 per share on revenue of $4.93 million. 
<h3>Companies Reporting After The Bell</h3>
• Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) is likely to report quarterly loss at $1.24 per share on revenue of $17.79 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

CAAS

HUMA

KPLT

LIQT

ZSPC

Earnings Scheduled For March 28, 2025

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) will release its quarterly earnings report on Friday, 2024-11-15. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate AIM ImmunoTech to report an earnings per share (EPS) of $-0.09.
Anticipation surrounds AIM ImmunoTech's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.09, leading to a 5.88% increase in the share price on the subsequent day.
Here's a look at AIM ImmunoTech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.09</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.06</td>
<td>-0.03</td>
<td>-0.12</td>
<td>-0.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-12.0%</td>
<td>6.0%</td>
<td>3.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1743084081_0.png" alt="eps graph" />
<h3>Performance of AIM ImmunoTech Shares</h3>
Shares of AIM ImmunoTech were trading at $0.129701 as of March 26. Over the last 52-week period, shares are down 73.07%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AIM/earnings">To track all earnings releases for AIM ImmunoTech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For AIM ImmunoTech

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.34) by 8.82 percent. This is a 48.33 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $170.000 thousand which beat the analyst consensus estimate of $145.000 thousand by 17.24 percent. This is a 15.84 percent decrease over sales of $202.000 thousand the same period last year.

Earnings Beats

AIM ImmunoTech FY 2024 GAAP EPS $(0.31) Beats $(0.34) Estimate, Sales $170.000K Beat $145.000K Estimate

AIM ImmunoTech Cash Position As Of Dec. 31 $4M

Insider Trades

AIM ImmunoTech Form 4 Filing Shows CEO Thomas K Equels Bought 50,000 Shares At An Average Price Of $0.13/Share

<a href="https://www.globenewswire.com/Tracker?data=NeyO0wGM43gbUdLddt0f5TtBAE5dYWZWTqxkBZA9m8x4zjEjTwMtpeR-4apnEbiMqe2uutaspjVxiSX0L8RC_yGztjzK75rerkqephqUtlI=">AIM ImmunoTech Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>)&nbsp;("AIM" or the "Company") today announced that it received notice from the NYSE American (the "American") that the American has accepted the Company's Plan to regain compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the American Company Guide. AIM has until June 11, 2026 to regain compliance with the NYSE's Continued Listings Standards.

NYSE American Accepts AIM ImmunoTech's Plan To Regain Listing Compliance

AIM Doses First New Subject In Phase 2 Study Of Ampligen and Imfinzi For Late-Stage Pancreatic Cancer

AIM ImmunoTech shares are trading higher after the company announced it will not proceed with an offering under its Form S-1 registration statement until after filing its annual report.

AIM ImmunoTech Will Not Proceed With Offering Pursuant To Registration Statement on Form S-1 Until After Filing Annual Report

Aim ImmunoTech Announces Its Initiation Of Plan To Advance Ampligen As A Vaccine Adjuvant For Avian Influenza

AIM ImmunoTech Granted Safety Committee Approval To Proceed With Phase 2 Study Of Ampligen With Imfinzi

AIM ImmunoTech Announces Study 'Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions' Was Posted To ClinicalTrials.gov

Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS
The early-onset broad-spectrum antiviral effect of Ampligen has been observed to stimulate strong innate immune response, offering potential therapeutic benefits for people with ME/CFS or Post-COVID chronic fatigue
OCALA, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Lp7r-Zko8_STxa2-SCTwWJh1YHEsWboXq5jsxeXHg-SqFEWiqVGMujh5tpqwQxZY5yu2XZuEKP-kqNipNfkoTz27dgqboQ8x6ThGGR7FHqU=">AIM ImmunoTech Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>)&nbsp;("AIM" or the "Company") today offered commentary on a new article in the Journal of General Internal Medicine linking COVID-19 to increased risk of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome ("ME/CFS").
The article, titled "<a href="https://www.globenewswire.com/Tracker?data=Fpq1FisR8Jo1G0UQe1w_Xfyq974COCvW4D_zDbhx6_5A0ny4E4Th5BAnjftaot2-CBsrvkrvPy4vLK9ZH3_XPf6BEtDKxILgAsWUrhbxQtb9G1eL_d0RHXTAtQyiV1dDgtvGWyL_CXYP8dEKM0sl_e5o6kWll7Ml4HPjKmEAZbaCJFKGMw0km6H3jqqnBplMJoqzXHwWq6c0FZBZ48Kk9SNpfqFRHl4ud2cVHkg-JSiJXXFaA4j39hkqvOp3hWvEPVi255ewcc5zYELBzc3yQw==">Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study</a>," found that among study participants infected with SARS-CoV-2, the incidence of ME/CFS was 15 times higher than pre-pandemic rates. The article's lead author, Suzanne D. Vernon, PhD, emphasized the following highlights in an <a href="https://www.globenewswire.com/Tracker?data=IFH4V9qJpmVon0e6WwLx9F-9dJ-PXSwcqmf6AWGKFGpioE4g2C0XT-vTSog6ur1kSKv3Tqel3TlMk2tZv_ZxO8FrpaAyqaJe6oAT9qQmwriMCO59gtO7iuWk983XNcr_9yKUh6iDzSoInm9YYBi9MQ==">accompanying analysis</a> posted to the Bateman Horne center website:
<ul>
<li>Of the 4,515 participants who enrolled within 30 days of contracting COVID-19, 73 developed ME/CFS at least six months post-infection.</li>
<li>In total, 531 participants met ME/CFS criteria, translating to a prevalence of 4.5% among those infected—nearly eight times higher than uninfected participants.</li>
<li>This prevalence is five times higher than pre-pandemic estimates and underscores the severe and lasting impact of COVID-19 on public health.
<ul>
<li>90% of these post-COVID-19 ME/CFS cases clustered with the most symptomatic and severe cases of Long COVID, highlighting the overlap between these two conditions.</li>
</ul>
</li>
</ul>

AIM ImmunoTech Announces Commentary On Study Linking COVID-19 To Increased ME/CFS Risk; Incidence 15 Times Higher Than Pre-Pandemic Rates; Ampligen Shows Strong Antiviral Effect Beneficial For ME/CFS And Post-COVID Fatigue; 531 Of 4,515 Participants Affected

Press Releases

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

Legal

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

AIM ImmunoTech Resumes Trading on NYSE American

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

Comments

AIM ImmunoTech

AIM ImmunoTech (AIM) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO